Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. Buys 1,200,000 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. acquired 1,200,000 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was purchased at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the acquisition, the director now directly owns 9,317,246 shares in the company, valued at approximately $416,946,758.50. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Janux Therapeutics Stock Up 4.6 %

Shares of NASDAQ JANX opened at $52.80 on Wednesday. The business has a 50-day moving average price of $46.09 and a 200 day moving average price of $45.63. The stock has a market cap of $2.74 billion, a PE ratio of -43.28 and a beta of 3.54. Janux Therapeutics, Inc. has a 52-week low of $5.65 and a 52-week high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to the consensus estimate of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The firm’s quarterly revenue was up 709.1% on a year-over-year basis. Sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Stifel Nicolaus assumed coverage on Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price target on the stock. Wedbush restated an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Scotiabank lowered their price objective on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Janux Therapeutics in a research report on Monday, August 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $66.13.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Summit Securities Group LLC purchased a new stake in Janux Therapeutics during the 2nd quarter valued at approximately $29,000. Amalgamated Bank raised its stake in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares during the last quarter. Plato Investment Management Ltd purchased a new stake in Janux Therapeutics during the 2nd quarter valued at approximately $42,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $151,000. Finally, AQR Capital Management LLC purchased a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $215,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.